Overall, we found no differences regarding the risk of stroke/TE, but apixaban was associated with a 21% lower relative risk of major bleeding compared to VKA. This risk reduction was even greater when comparing apixaban to VKA among patients with eGFR 15-30 mL/min/1.73 m2, and when comparing apixaban to dabigatran and rivaroxaban among patients with eGFR 30-49 mL/min/1.73 m2.
Daniele Pastori, Professor Gregory Lip, Angela Sciacqua, Francesco Perticone, Francesco Melillo, Cosmo Godino, Rossella Marcucci, Martina Berteotti, Francesco Violi, Pasquale Pignatelli
Professor Gregory Lip, Allison Keshishian, A Kang, X Luo, Nipun Atreja, Y Zhang, Patricia Schuler, Jenny Jiang, K Lovett, Hüseyin Yüce, Steven Deitelzweig
Laila Stærk, Emil Loldrup Fosbøl, Professor Gregory Lip, Morten Lamberts, Anders Nissen Bonde, Christian Torp‐Pedersen, Brice Ozenne, Thomas Alexander Gerds, Gunnar Gislason, Jonas Bjerring Olesen
Discussion(0)
No comments yet. Be the first to comment.